Core One Labs Inc.

COOL

CA21872J3073

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 03:54:26 2024-04-23 pm EDT			5-day change	1st Jan Change
0.18 ^CAD	-10.00%		-7.69%	-37.93%

Apr. 09	Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding	CI
Feb. 29	Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 29, 2022 at 03:52 pm EDT

Core One Labs Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was CAD 0.136386 million. Net loss was CAD 0.041173 million compared to CAD 5.9 million a year ago.
For the six months, sales was CAD 0.268445 million. Net loss was CAD 12.01 million compared to CAD 30.15 million a year ago. Basic loss per share from continuing operations was CAD 0.43 compared to CAD 2.28 a year ago.

Latest news about Core One Labs Inc.

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding	Apr. 08	CI
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 29	CI
Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 03	CI
Core One Labs Inc. announced that it has received CAD 0.2 million in funding	23-09-17	CI
Core One Labs Inc. announced that it expects to receive CAD 1 million in funding	23-09-10	CI
Core One Labs Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer?s and Parkinson's Disease	23-08-04	CI
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023	23-08-03	CI
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer?s and Parkinson?s Disease	23-07-28	CI
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process	23-07-12	MT
Core One's Vocan Files International Patent For Breakthrough Proprietary Biosynthetic Psilocybin Production Method	23-07-10	MT
Core One Labs Inc. Applauds FDA's Draft Guidance on Clinical Trials for Psychedelic Drugs	23-06-27	CI
Core One Labs Says in Talks with Multiple Companies to Supply Psilocybin; COOL Gained 15% on Friday	23-05-08	MT
Core One Labs Inc. in Talks with Multiple Companies to Supply Psilocybin	23-05-05	CI
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization	23-05-02	MT
Core One Labs Completes Synthetic Production of Psilocin at GMP Certified Manufacturing Facility; Surges Nearly 26% in Frankfurt Trading	23-04-24	MT
Core One Labs Applauds Study Linking Psychedelic Treatment to Substantial Reduction in Alcohol Misuse & Ptsd Symptoms in Us Special Operations Forces Veterans	23-04-04	CI
Core One Labs Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Core One Labs Inc. Announces Management Changes	23-01-24	CI
Core One Labs' Buys GMP Drug Inc.; Says "Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution	23-01-16	MT
Core One Labs Inc. completed the acquisition of GMP Drug Inc. for CAD 3.5 million.	23-01-12	CI
Core One Labs Inc. acquired GMP Drug Inc. for CAD 3.5 million.	23-01-12	CI
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin	22-11-18	CI
European University to Fund Akome Biotech's Neurogenesis Stimulation Studies; Core One Labs Gained 15.5% on Friday	22-10-17	MT

Chart Core One Labs Inc.

Duration

Period

More charts

Company Profile

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
CORE ONE LABS INC.	-37.93%	6.18M
DONG-E-E-JIAO CO.,LTD.	+37.37%	6.05B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.69%	4.45B
TASLY PHARMACEUTICAL GROUP CO., LTD	-12.46%	3.06B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.12%	3.04B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.47%	2.58B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+36.06%	1.79B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.84%	1.66B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-10.60%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.03%	1.54B